Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DG3173 (Somatoprim) in Untreated Acromegaly
NCT02217800Phase 2Completed
- Sponsor
- Aspireo Pharmaceuticals Ltd.
- Start
- Nov 2013
- Primary completion
- Mar 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of veldoreotide in acromegaly, sponsored by Aspireo Pharmaceuticals Ltd.. Started Nov 2013; status: completed.
02
Drugs
veldoreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT02217800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217800.